Christopher D. Earl
President at Innotrove LLC
Profile
Christopher D.
Earl is currently the Director at Asuragen, Inc. and the President at Innotrove LLC.
He previously worked as the President & Chief Executive Officer at Avitech Diagnostics, Inc. and as a Director at Replidyne, Inc., Daktari Diagnostics, Inc., AdvanDx, Inc., Mirna Therapeutics, Inc., and Decipher Biosciences, Inc. He was also the Managing Director at Perseus Capital, Inc. and the President at Bio Ventures for Global Health from 2010 to 2013.
Earl holds a doctorate degree from Harvard University and an undergraduate degree from the University of Pennsylvania.
Christopher D. Earl active positions
Companies | Position | Start |
---|---|---|
Asuragen, Inc.
Asuragen, Inc. Medical SpecialtiesHealth Technology Asuragen, Inc. develops molecular diagnostic products. Its products include AmplideX and QuantideX. It uses genomics to drive patient management through clinical testing solutions. The company was founded in March 2006 by Matthew M. Winkler and is headquartered in Austin, TX. | Director/Board Member | 2011-05-15 |
Innotrove LLC
Innotrove LLC Miscellaneous Commercial ServicesCommercial Services Innotrove LLC provides biotechnology services. The private company is based in Arlington, VA. | President | - |
Former positions of Christopher D. Earl
Companies | Position | End |
---|---|---|
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | Director/Board Member | 2008-03-26 |
Veracyte SD, Inc.
Veracyte SD, Inc. Miscellaneous Commercial ServicesCommercial Services Decipher Biosciences, Inc. is a commercial-stage precision oncology company which engages in patient care improvement. The Company?s differentiated approach measures the biological activity of a patient?s entire tumor genome, known as whole transcriptome analysis, and applies proprietary machine learning algorithms to improve therapy selection and accelerate adoption of new therapies into the standard of care. Its novel prostate cancer genomic testing products examine the underlying biology of a patient?s tumor, enabling physicians to select an optimal therapy. The firm?s whole transcriptome analysis of clinical patient samples from its commercial channel and its participation in practice-changing clinical trials has allowed it to build and expand its Decipher GRID database GRID. The company was founded by Elai Davicioni, Timothy J. Triche, Bruce A. Schmidt, and Jonathan D. Buckley and is headquartered in San Diego, CA. | Director/Board Member | - |
AdvanDx, Inc.
AdvanDx, Inc. Medical SpecialtiesHealth Technology AdvanDx, Inc. provides advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. Its products include QuickFISH BC Tests, PNA FISH Tests, ASR PNA Probes, starter system, accessories and package inserts. The firm offers diagnostic solutions that include antimicrobial stewardship, blood culture contamination, staphylococcal bacteremia, enterococcal bacteremia, gram-negative bacteremia and candidemia. The company was founded by Henrik Stender and Thais T. Johansen in 2002 and is headquartered in Woburn, MA. | Director/Board Member | - |
Daktari Diagnostics, Inc.
Daktari Diagnostics, Inc. Medical SpecialtiesHealth Technology Daktari Diagnostics, Inc. operates as a holding company that provides healthcare solutions. The firm engages in the development of point-of-care diagnostic systems for global health applications. Its product includes Daktari Virology which detects HIV and HCV, Daktari InSight which provides data management services, and Daktari Sickle Cell which detects sickle cell disease on infants. The company was founded by William Rodriguez in 2008 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Perseus Capital, Inc.
Perseus Capital, Inc. Investment ManagersFinance Part of Nymbus Capital Group, Inc., Perseus Capital, Inc. is a Canadian company that provides investment management services. The private company is based in Montréal, Canada. The company was founded in 2005 by Jean Turmel. Perseus Capital was acquired by Nymbus Capital Group, Inc. on January 21, 2021. | Chief Executive Officer | - |
Training of Christopher D. Earl
Harvard University | Doctorate Degree |
University of Pennsylvania | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 10 |
---|---|
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | Health Technology |
Asuragen, Inc.
Asuragen, Inc. Medical SpecialtiesHealth Technology Asuragen, Inc. develops molecular diagnostic products. Its products include AmplideX and QuantideX. It uses genomics to drive patient management through clinical testing solutions. The company was founded in March 2006 by Matthew M. Winkler and is headquartered in Austin, TX. | Health Technology |
Daktari Diagnostics, Inc.
Daktari Diagnostics, Inc. Medical SpecialtiesHealth Technology Daktari Diagnostics, Inc. operates as a holding company that provides healthcare solutions. The firm engages in the development of point-of-care diagnostic systems for global health applications. Its product includes Daktari Virology which detects HIV and HCV, Daktari InSight which provides data management services, and Daktari Sickle Cell which detects sickle cell disease on infants. The company was founded by William Rodriguez in 2008 and is headquartered in Cambridge, MA. | Health Technology |
Avitech Diagnostics, Inc. | Health Technology |
Bio Ventures for Global Health | |
Perseus Capital, Inc.
Perseus Capital, Inc. Investment ManagersFinance Part of Nymbus Capital Group, Inc., Perseus Capital, Inc. is a Canadian company that provides investment management services. The private company is based in Montréal, Canada. The company was founded in 2005 by Jean Turmel. Perseus Capital was acquired by Nymbus Capital Group, Inc. on January 21, 2021. | Finance |
AdvanDx, Inc.
AdvanDx, Inc. Medical SpecialtiesHealth Technology AdvanDx, Inc. provides advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. Its products include QuickFISH BC Tests, PNA FISH Tests, ASR PNA Probes, starter system, accessories and package inserts. The firm offers diagnostic solutions that include antimicrobial stewardship, blood culture contamination, staphylococcal bacteremia, enterococcal bacteremia, gram-negative bacteremia and candidemia. The company was founded by Henrik Stender and Thais T. Johansen in 2002 and is headquartered in Woburn, MA. | Health Technology |
Veracyte SD, Inc.
Veracyte SD, Inc. Miscellaneous Commercial ServicesCommercial Services Decipher Biosciences, Inc. is a commercial-stage precision oncology company which engages in patient care improvement. The Company?s differentiated approach measures the biological activity of a patient?s entire tumor genome, known as whole transcriptome analysis, and applies proprietary machine learning algorithms to improve therapy selection and accelerate adoption of new therapies into the standard of care. Its novel prostate cancer genomic testing products examine the underlying biology of a patient?s tumor, enabling physicians to select an optimal therapy. The firm?s whole transcriptome analysis of clinical patient samples from its commercial channel and its participation in practice-changing clinical trials has allowed it to build and expand its Decipher GRID database GRID. The company was founded by Elai Davicioni, Timothy J. Triche, Bruce A. Schmidt, and Jonathan D. Buckley and is headquartered in San Diego, CA. | Commercial Services |
Innotrove LLC
Innotrove LLC Miscellaneous Commercial ServicesCommercial Services Innotrove LLC provides biotechnology services. The private company is based in Arlington, VA. | Commercial Services |
Mirna Therapeutics, Inc.
Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mirna Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of microRNA-based oncology therapeutics. Its products includes miR-34, miR-215, miR-101, miR-16, and let-7. The company was founded Matthew M. Winkler in 2007 and is headquartered in Austin, TX. | Commercial Services |
- Stock Market
- Insiders
- Christopher D. Earl